Immtech Pharmaceuticals signed a Memorandum of Understanding (MOU) declaring its interest in developing a strategic alliance with Beijing Pharmaceutical Group Co. Ltd. (BPGC). The MOU also confirms BPGC’s intention to consider a range of collaborative opportunities with Immtech. The alliance would give BPGC rights to develop drugs from Immtech’s library of compounds, which primarily target hepatitis C and malaria. No financial disclosures were made at this early stage. More details...

Stock Symbol: (NYSE Alternext US: IMM)